Team:PennState/smartfold/overview

From 2008.igem.org

(Difference between revisions)
m (Smartfold/overview moved to Team:PennState/smartfold/overview: This is part of our team wiki. Page created in the wrong place.)
Line 152: Line 152:
-->
-->
<td valign="top" width="20%" id="projectnav">
<td valign="top" width="20%" id="projectnav">
-
  <h4 style="margin-top: 0;">Hormone Biosensors</h4>
+
  <h4>Diauxie Elimination</h4>
  <dl id="hbnav">
  <dl id="hbnav">
 +
  <dd><a href="https://2008.igem.org/Team:PennState/diauxie/intro">Introduction</a></dd>
 +
  <dd><a href="https://2008.igem.org/Team:PennState/diauxie/overview">Overview</a></dd>
 +
  <dd><a href="https://2008.igem.org/Team:PennState/diauxie/parts" title="Parts submitted to the registry for this project">Parts</a></dd>
 +
  <dd><a href="https://2008.igem.org/Team:PennState/diauxie/references">References</dd>
 +
</dl>
 +
<h4>Hormone Biosensors</h4>
 +
<dl id="denav">
   <dd><a href="hbintro" title="Intro to Endocrine Disruption, pseudoestrogens, pthalates, nuclear hormone receptors, and our goals">Introduction</a></dd>
   <dd><a href="hbintro" title="Intro to Endocrine Disruption, pseudoestrogens, pthalates, nuclear hormone receptors, and our goals">Introduction</a></dd>
   <dt>Smart Fold</dt>
   <dt>Smart Fold</dt>
-
   <dd><a href="smartfold/overview">Overview</a></dd>
+
   <dd><a href="https://2008.igem.org/Team:PennState/smartfold/overview">Overview</a></dd>
-
   <dd><a href="smartfold/parts" title="Parts submitted to the registry for this project">Parts</a></dd>
+
   <dd><a href="https://2008.igem.org/Team:PennState/smartfold/parts" title="Parts submitted to the registry for this project">Parts</a></dd>
-
   <dd><a href="smartfold/references">References</a></dd>
+
   <dd><a href="https://2008.igem.org/Team:PennState/smartfold/references">References</a></dd>
   <dt>Nuclear Fusion</dt>
   <dt>Nuclear Fusion</dt>
-
   <dd><a href="fusion/overview">Overview</a></dd>
+
   <dd><a href="https://2008.igem.org/Team:PennState/fusion/overview">Overview</a></dd>
-
   <dd><a href="fusion/parts" title="Parts submitted to the registry for this project">Parts</a></dd>
+
   <dd><a href="https://2008.igem.org/Team:PennState/fusion/parts" title="Parts submitted to the registry for this project">Parts</a></dd>
-
   <dd><a href="fusion/references">References</a></dd>
+
   <dd><a href="https://2008.igem.org/Team:PennState/fusion/references">References</a></dd>
-
</dl>
+
-
<h4>Diauxie Elimination</h4>
+
-
<dl id="denav">
+
-
  <dd><a href="diauxie/intro">Introduction</a></dd>
+
-
  <dd><a href="diauxie/overview">Overview</a></dd>
+
-
  <dd><a href="diauxie/parts" title="Parts submitted to the registry for this project">Parts</a></dd>
+
-
  <dd><a href="diauxie/references">References</dd>
+
  </dl>
  </dl>
</td>
</td>

Revision as of 18:54, 27 October 2008

Diauxie Elimination

Introduction
Overview
Parts
References

Hormone Biosensors

Introduction
Smart Fold
Overview
Parts
References
Nuclear Fusion
Overview
Parts
References

Smart Fold Project In Depth

The human PPAR has three different types α, β, and γ but only two show any affect by phthalates. We are using the alpha form which is expressed in the liver, kidney, heart, muscle, adipose tissue, and others. There are different regions associated with nuclear hormone receptors: N-terminal, DNA binding domain (DBD), Hinge, Ligand binding domain (LBD), and C-terminal. The LBD is the region that attracts and holds the ligand of interest. After ligand binding the receptor usually will form a dimer, in our case PPAR will combine with Retinoid X Receptor (RXR) to form a heterodimer. The RXR protein functions much like the PPAR but in this case it does not need to attach a ligand before dimerization. The heterodimer will bind to Peroxisome Proliferator Response Element (PPRE) via the DBD and activates transcription. Most often a coactivator complex is required for transcriptional activation which involves proteins SRC-1, CBP and others.

This Smart Fold Reporter project uses altered growth conditions so that the entire PPAR protein is successfully expressed and used to transcriptionally report for the presence of phthalates. Expressing the entire PPAR in E. Coli has proven difficult which could be caused by toxicicity to the cells from the DBD. To overcome this problem we are going to treat the E. Coli with carbonyl cyanide m-chlorophenyl-hydrazone (CCCP) which is an uncoupler of oxidative phosphorylation. This strategy would correlate to the heat shock proteins involved with synthesis in the human body. The cells that have the PPAR plasmid will be grown on plates containing Timentin (a combination of Ticarcillin and clavulanic acid) which prevents growth of bacteria without plasmid more strongly than Ampicillin alone. The expression of the PPAR and RXR also need tight regulation so the arabinose operon will be used. A green fluorescent protein will be placed after the PPRE to signal transcription after heterodimer binding.